WO2008014613A1 - Multifunctional bioactive compounds - Google Patents
Multifunctional bioactive compounds Download PDFInfo
- Publication number
- WO2008014613A1 WO2008014613A1 PCT/CA2007/001357 CA2007001357W WO2008014613A1 WO 2008014613 A1 WO2008014613 A1 WO 2008014613A1 CA 2007001357 W CA2007001357 W CA 2007001357W WO 2008014613 A1 WO2008014613 A1 WO 2008014613A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- group
- compound according
- aryl
- trp
- Prior art date
Links
- 0 CC(*(*)C(*(C)*1C)=O)C1=O Chemical compound CC(*(*)C(*(C)*1C)=O)C1=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
- C07H5/06—Aminosugars
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to compounds, compositions, methods, and applications of a novel approach to administer bioactive compounds to patients in need thereof.
- Radiotherapy and chemotherapy are well-established treatment methods for malignant diseases.
- Cells which grow and divide rapidly, are most vulnerable to the effects of radiation and cytotoxic agents.
- Among those effected are tumor cells, and normal cells including hair and intestinal cells, and cells of the hemopoietic and immune systems. Damage to normal cells of the hemopoietic and immune systems by radiation and cytotoxic agents often has life-threatening consequences, and it limits the ability to administer a full therapeutic dose.
- transforming growth factor beta-1 has been reported to be useful for protecting hematopoietic stem cells from the myelotoxicity of chemotherapeutic drugs or radiation therapy (U.S. Patent No. 5,278,145 to Keller et al.).
- a lyophilized composition containing human albumin in thymosin alpha 1 was also reported to exert a preventative activity against progression of leukemia in mice whose immune systems were severely damaged by treatment with cytostatic agents or radiation treatment.
- Hemopoietic growth factors such as interleukin-3 and CSF have been used to potentiate immune response or assist in reconstituting normal blood following radiation-or-chemotherapy-induced hematopoietic cell suppression (WO 88/05469 to Anderson et al., U.S. 4,959,455 to Ciarletta et al; U.S. 4,999,291 to Souza).
- X is hydrogen, glycine, alanine, leucine, isoleucine, valine, N-valine, proline, tyrosine, phenylalanine, tryptophan, D-alanine, D-leucine, D-isoleucine, D-valine, D- N-valine, D-proline, D-tyrosine, D-phenylalanine, D-tryptophan, ⁇ -aminobutyric acid or ⁇ -aminocaproic acid;
- Y is glycine, alanine, leucine, isoleucine, valine, N-valine, proline, tyrosine, phenylalanine, tryptophan, D-alanine, D-leucine, D-isoleucine, D- valine, D-N-valine, D-proline, D-tyrosine, D-phenylalanine, D-phenylalanine, D-
- X is hydrogen, glycine, alanine, leucine, isoleucine, valine, N-valine, proline, tyrosine, phenylalanine, tryptophan, D- alanine, D-leucine, D-isoleucine, D-valine, D-N-valine, D-proline, D-tyrosine, D- phenylalanine, D-tryptophan, ⁇ -aminobutyric acid or ⁇ -aminocaproic acid; A is D- glutamic acid or D- ⁇ -glutamic acid; and Y is glycine, alanine, leucine, isoleucine, valine, N-valine, proline, tyrosine, phenylalanine, tryptophan, D-alanine, D-leucine, D-isoleucine, D-valine
- X is hydrogen, arginine, D-arginine, ornithine, D-ornithine, lysine, D-lysine, homoarginine, D-homoarginine, citrulline, D- citrulline; Tyr is tyrosine; Y is D-alanine, D-valine, D-leucine, D-isoleucine, D- phenylalanine, D-asparagine, D-tryptophan, D-proline, D-serine, D-threonine, D- tyrosine, D-hydroxyproline, D-cysteine, D-cysteyl-cysteine, D-methionine, D-lysine, D-homoarginine, D-arginine, D-histidine,
- compositions for the delivery, in particular, oral delivery, of active agents comprising a diketopiperazine-based system are described in several patents and patent applications owned by Emisphere Technologies, Inc., including for example, U.S. Patent Nos. 6,663,898, 6,395,774, 6,331,318, 5,976,569 and 5,693,338, as well as U.S. Patent Application Nos. 20030198658, 20030155993 and 20030028250.
- the diketopiperazine is typically added as a separate component.
- the present invention represents a new platform for the therapeutic delivery of multifunctional bioactive compounds.
- the invention relates to molecules that possess an immunoregulatory portion linked to a stabilizer moiety.
- the stabilizer moiety acts as an effective carrier for the immunoregulator into the body.
- the immunoregulator and stabilizer may be optionally linked to another functionally bioactive molecule.
- the bioactive molecule possesses either further immunoregulatory activity, activity which complements or synergizes with the immunoregulatory portion or a different therapeutic activity.
- the present invention includes a multifunctional bioactive compound selected from one or more of a compound of Formula I:
- A is an immunoregulatory radical selected from the group consisting of Trp, Tyr, Phe, His, aryl and heteroaryl, where the aryl and heteroaryl groups may be optionally substituted with 1 to 6 substituents independently selected from the group consisting of halo, OH, OCi -6 alkoxy, C, -6 alkyl, C 2-6 alkenyl, C 2-6 alkenyloxy, NH 2 , NH(C 1-6 alkyl), N(C 1-6 alkyl)(C 1-6 alkyl), CN, CF 3 , OCF 3 , NO 2 , C(O)C 1-6 alkyl, C(O)OC 1-6 alkyl, SO 2 C 1- 6 alkyl, SO 2 NH 2 , SO 2 NHC i -6 alkyl, phenyl and Ci -6 alkylenephenyl, and where heteroaryl is an aromatic carbocyclic ring containing from 5 to 10 carbon atoms, in which 1 to 4 carbon atoms have
- L 1 and L 2 are each independently a linker group selected from the group consisting of a single bond, -C(O)- -C(O)NR 2 -, -NR 2 C(O)-, -NR 2 -, -C(O)-O-, -OC(O)-, -S-S-, SO 2 NR 2 -, NR 2 SO 2 , -S- and -O- ;
- R 2 is selected from the group consisting of H, Ci -6 alkyl, Ci -6 alkylenearyl, C(O)Ci-
- R 5 is H or Ci -6 alkyl
- n is an integer between O and 50;
- D is selected from the group consisting of H, Ci -6 alkyl, any side chain of an amino acid and any functionally active molecule, and pharmaceutically acceptable salts, solvates and prodrugs thereof.
- the present invention further relates to pharmaceutical compositions comprising a multifunctional bioactive compound of the invention and a pharmaceutically acceptable carrier.
- Also included in the present invention are methods of treating immune disorders, and optionally other disorders in the same subject, comprising administering an effective amount of a multifunctional bioactive compound of the invention to a subject in need thereof. Further, there is provided a use of a multifunctional bioactive compound of the invention to treat immune disorders, and optionally other disorders in the same subject, as well as a use of a multifunctional bioactive compound of the invention to prepare a medicament to treat immune disorders, and optionally other disorders in the same subject.
- Figure 1 is a NMR spectrum of cyclo-L-Ala-L-Glu-(L-Trp-OMe), which is a compound of one embodiment of the present invention.
- Figure 2 shows the titration dilution graph of OVA + CFA.
- Figure 3 shows the titration dilution graph of compounds 33a, 33b, 17 and OVA.
- Figure 4 shows a graph illustration the adjuvant activity of compounds 17, 19, 26a, 26b, 33a, 33b and OVA.
- Ph means phenyl
- Me means methyl
- alkyl as used herein means straight and/or branched chain alkyl groups containing from one to six carbon atoms and includes methyl, ethyl, propyl, isopropyl, t-butyl, pentyl, hexyl and the like.
- alkoxy as used herein means straight and/or branched chain alkoxy groups containing from one to six carbon atoms and includes methoxy, ethoxy, propyloxyl, isopropyloxy, t-butoxy, hexyloxy and the like.
- alkenyl as used herein means straight and/or branched chain alkenyl groups containing from two to six carbon atoms and one to three double bonds and includes vinyl, allyl, 1-butenyl, 2-hexenyl and the like.
- alkenyloxy as used herein means straight and/or branched chain alkenyloxy groups containing from two to six carbon atoms and one to three double bonds and includes vinyloxy, allyloxy, propenyloxyl, butenyloxy, hexenyloxy and the like.
- alkylene as used herein means bifunctional straight and/or branched alkyl radicals containing the specified number of carbon atoms.
- halo as used herein means halogen and includes chloro, fluoro, bromo, iodo and the like.
- pharmaceutically acceptable means compatible with the treatment of animals, in particular, humans.
- pharmaceutically acceptable salt means an acid addition salt or basic addition salt which is suitable for or compatible with the treatment of animals, in particular, humans.
- pharmaceutically acceptable acid addition salt means any non-toxic organic or inorganic salt of any base compound of the invention, or any of its intermediates.
- Basic compounds of the invention that may form an acid addition salt include those having a basic nitrogen, for example NH 2 and NHCi- 4alkyl.
- Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulfuric and phosphoric acids, as well as metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate.
- Illustrative organic acids that form suitable salts include mono-, di-, and tricarboxylic acids such as glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, benzoic, phenylacetic, cinnamic and salicylic acids, as well as sulfonic acids such as p-toluene sulfonic and methanesulfonic acids. Either the mono or di-acid salts can be formed, and such salts may exist in either a hydrated, solvated or substantially anhydrous form.
- mono-, di-, and tricarboxylic acids such as glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, benzoic, phenylacetic, cinnamic and salicylic acids, as well as sul
- the acid addition salts of the compounds of the invention are more soluble in water and various hydrophilic organic solvents, and generally demonstrate higher melting points in comparison to their free base forms.
- the selection of the appropriate salt will be known to one skilled in the art.
- Other non-pharmaceutically acceptable salts e.g. oxalates, may be used, for example, in the isolation of the compounds of the invention, for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt.
- pharmaceutically acceptable basic addition salt means any non-toxic organic or inorganic base addition salt of any acid compounds of the invention.
- Illustrative inorganic bases which form suitable salts include lithium, sodium, potassium, calcium, magnesium or barium hydroxide.
- Illustrative organic bases which form suitable salts include aliphatic, alicyclic or aromatic organic amines such as methylamine, trimethylamine and picoline or ammonia. The selection of the appropriate salt will be known to a person skilled in the art.
- solvate as used herein means a compound of the invention, or a pharmaceutically acceptable salt of a compound of the invention, wherein molecules of a suitable solvent are incorporated in the crystal lattice.
- a suitable solvent is physiologically tolerable at the dosage administered. Examples of suitable solvents are ethanol, water and the like. When water is the solvent, the molecule is referred to as a "hydrate".
- compound(s) of the invention means compound(s) of Formula I, and/or pharmaceutically acceptable salts, solvates and/or prodrugs thereof. It is to be clear that the present invention includes pharmaceutically acceptable salts, solvates and prodrugs of compounds of the invention and mixtures comprising two or more compounds of the invention, pharmaceutically acceptable salts of the compounds of the invention (where applicable), pharmaceutically acceptable solvates of the compounds of the invention and prodrugs of the compounds of the invention.
- an "effective amount” or a "sufficient amount” of an agent as used herein is that amount sufficient to effect beneficial or desired results, including clinical results, and, as such, an "effective amount” depends upon the context in which it is being applied. For example, in the context of administering an agent that acts as an immunomodulator, an effective amount of an agent is, for example, an amount sufficient to achieve such a modulation in immune response as compared to the response obtained without administration of the agent.
- treatment is an approach for obtaining beneficial or desired results, including clinical results.
- beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of disease, stabilized (i.e. not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable.
- Treatment can also mean prolonging survival as compared to expected survival if not receiving treatment.
- “Palliating" a disease or disorder means that the extent and/or undesirable clinical manifestations of a disorder or a disease state are lessened and/or time course of the progression is slowed or lengthened, as compared to not treating the disorder.
- modulate as used herein includes the inhibition or suppression of a function or activity (such as immune response) as well as the enhancement of a function or activity.
- a function or activity such as immune response
- a function or activity such as immune response
- a function or activity is to increase the function or activity when compared to otherwise same conditions except for a condition or parameter of interest, or alternatively, as compared to another conditions.
- subject as used herein includes all members of the animal kingdom including human.
- the subject is preferably a human,
- Compounds of the Invention The present invention relates to compounds comprising an immunoregulatory portion, a stabilizer portion and, optionally a further functionally active portion.
- the portions are together via various linker groups to provide a multifunctional compound that can be used to treat multiple disorders in the same subject.
- the present invention includes a multifunctional bioctive compound selected from one or more of a compound of Formula I:
- A is an immunoregulatory radical selected from the group consisting of Trp, Tyr, Phe, His, aryl and heteroaryl, where the aryl and heteroaryl groups may be optionally substituted with 1 to 6 substituents independently selected from the group consisting of halo, OH, OCi. 6 alkoxy, Ci -6 alkyl, C 2 . 6 alkenyl, C 2 . 6 alkenyloxy, NH 2 , NH(Ci -6 alkyl), N(C 1-6 alkyl)(C 1-6 alkyl), CN, CF 3 , OCF 3 , NO 2 , C(O)Ci -6 alkyl, C(O)OC 1-6 alkyl, SO 2 C,.
- heteroaryl is an aromatic carbocyclic ring containing from 5 to 10 carbon atoms, in which 1 to 4 carbon atoms have been replaced with a heteroatom selected from one or more of O, S and N-R 1 , where R 1 is selected from the group consisting of H, C 1-6 alkyl, C M alkylenearyl, C(O)Ci -6 alkyl, C(O)aryl, SO 2 Ci -6 alkyl and SO 2 aryl when the N atom is sp 3 hybridized, or is a lone pair of electrons when the N atom is sp 2 hybridized;
- L 1 and L 2 are each independently a linker group selected from the group consisting of a single bond, -C(O)- -C(O)NR 2 -, -NR 2 C(O)-, -NR 2 -, -C(O)-O-, -OC(O)-, -S-S-, SO 2 NR 2 -, NR 2 SO 2 , -S- and -0-;
- R 2 is selected from the group consisting of H, Ci -6 alkyl, Ci -6 alkylenearyl, C(O)Ci- 6 alkyl, C(O)aryl, SO 2 Ci -6 alkyl and S0 2 aryl;
- R 5 is H or Ci. 6 alkyl;
- n is an integer between O and 50;
- D is selected from the group consisting of H, any side chain of an amino acid and any functionally active molecule, and pharmaceutically acceptable salts, solvates and prodrugs thereof.
- A is an immunoregulatory radical.
- immunoregulatory radical refers to any aromatic- or heteroaromatic- containing group having immuno- or hemosuppressive activity or immuno- or hemostimulative activity.
- A is selected from the group consisting of Trp, Tyr, Phe, His, aryl and heteroaryl, where the aryl and heteroaryl groups may be optionally substituted with 1 to 6 substituents independently selected from the group consisting of halo, OH, OCi_ 6 alkoxy, Ci -6 alkyl, C 2-6 alkenyl, C 2 .
- heteroaryl is an aromatic carbocyclic ring containing from 5 to 10 carbon atoms, in which 1 to 4 carbon atoms have been replaced with a heteroatom selected from one or more of O, S and N-R 1 , where R 1 is selected from the group consisting of H, C].
- Ci -6 alkylenearyl C(O)C i -6 alkyl, C(O)aryl, SO 2 Ci_ 6 alkyl and S0 2 aryl when the N atom is sp 3 hybridized, or is a lone pair of electrons when the N atom is sp 2 hybridized.
- A is selected from the group consisting of Trp, Tyr, Phe, His, aryl and heteroaryl, where the aryl and heteroaryl groups may be optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, OH, OCi -4 alkoxy, Ci -4 alkyl, C 2-4 alkenyl, C 2-4 alkenyloxy, NH 2 , NH(C M alkyl), N(C M alkyl)(C 1-4 alkyl), CN, CF 3 , OCF 3 , NO 2 , C(O)C 1-4 alkyl, C(O)OC l-4 alkyl, SO 2 Ci -4 alkyl, SO 2 NH 2 , SO 2 NHC , -4 alkyl, phenyl and Ci -4 alkylenephenyl, and where heteroaryl is an aromatic carbocyclic ring containing from 5 to 10 carbon atoms, in which 1 to 3 carbon atoms have been replaced
- A is selected from the group consisting of Trp, aryl and heteroaryl, wherein aryl is phenyl or naphthyl and heteroaryl is pyridinyl, imidazolyl, thienyl, furanyl, indolyl, isoquinolinyl, quinolinyl, benzothienyl, benzofuranyl, benzothiazolyl, thiazolo, benzooxazolyl, benzoisoxazolyl, benzoisothiazolyl or the like, with the indole ring of Trp, aryl and heteroaryl being unsubstituted or substituted with 1 to 2 substituents independently selected from the group consisting of halo, OH, OCi- 4 alkoxy, C M alkyl, C 2-4 alkenyl, C 2-4 alkenyloxy, NH 2 , NH(C ]-4 alkyl), N(Ci -4 alkyl
- the amine may be mono or dialkylated with Ci -6 alkyl, acylated with a C(O)C i -6 alkyl or converted to NH 3 + by addition of a pharmaceutically acceptable acid.
- the carboxyl group may be esterified, for example as a Ci- ⁇ alkyi ester, converted to the corresponding amide which may also be mono- or diesterified with C] -6 alkyl, converted to its corresponding hydrazine or to its corresponding basic addition salt.
- the immuno- and hemomodulating activity of this group may be controlled by the stereochemistry at the ⁇ -carbon.
- A is a group having the formula II:
- R 3 is selected from the group consisting of H, OCi -6 alkyl, NH 2 , NHCi- 6 alkyl, N(Ci -6 alkyl) 2 , NHNH 2 and OY, where Y is a pharmaceutically acceptable cation;
- R 4 is 1 to 4 substituents which are independently selected from the group consisting of H, halo, OH, OCi -6 alkoxy, C, -6 alkyl, Ci -6 alkenyl, C, -6 alkenyloxy, NH 2 , NH(Ci- 6 alkyl), N(C , -6 alky I)(C 1-6 alkyl), CN, CF 3 , OCF 3 , NO 2 , C(O)C i -6 alkyl, C(O)OC, -6 alkyl, SO 2 Ci -6 alkyl, SO 2 NH 2 , SO 2 NHC i -6 alkyl, phenyl and Ci -6 alkylenephenyl;
- the present invention includes compounds of Formula I wherein R 3 is selected from the group consisting of H, OCi -6 alkyl, NH 2 , NHC l-6 alkyl, N(C ]-6 alkyl) 2 , NHNH 2 and OY, where Y is a pharmaceutically acceptable cation.
- R 3 is selected from the group consisting of H, NH 2 , NHCi- 4 alkyl, N(Ci -4 alkyl) 2 , NHNH 2 and OY.
- R 3 is selected from the group consisting of H, Me, NH 2 , NHMe, NMe 2 , NHNH 2 and OY.
- the cation "Y” may be any pharmaceutically acceptable cation, for example Na + , K + and Zn 2+ .
- the compounds of Formula I also include those in which R 4 is 1 to 4 substituents which are independently selected from the group consisting of H, halo, OH, OC,. 6 alkoxy, C, -6 alkyl, C )-6 alkenyl, Ci -6 alkenyloxy, NH 2 , NH(C, -6 alkyl), N(Ci- 6 alkyi ⁇ C 1-6 alkyl), CN, CF 3 , OCF 3 , NO 2 , C(O)C ,.
- R 4 is 1 to 3 substituents which are independently selected from the group consisting of H, halo, OH, OCi -4 alkoxy, C 2-4 alkenyl, C 2-4 alkenyloxy, NH 2 , NH(C,.
- R 4 is 1 to 3 substituents which are independently selected from the group consisting of H, halo, OH, OMe, Me, vinyl, vinyloxy, NH 2 , NHMe, NHMe 2 , CN, CF 3 , OCF 3 , NO 2 , C(O)Me, C(O)OMe, SO 2 Me, SO 2 NH 2 , SO 2 NHMe, phenyl and benzyl.
- R 4 is a substituent selected from the group consisting of H, halo, OH, OMe, Me, vinyl, vinyloxy, NH 2 , NHMe, NHMe 2 , CN, CF 3 , OCF 3 , NO 2 , C(O)Me, C(O)OMe, SO 2 Me, SO 2 NH 2 , SO 2 NHMe, phenyl and benzyl.
- R 4 is H.
- each of L 1 and L 2 is a linker group independently selected from the group consisting of a single bond, -C(O)-, -C(O)NR 2 -, -NR 2 C(O)-, -NR 2 -, -C(O)-O-, -OC(O)-, -S-S-, SO 2 NR 2 -, NR 2 SO 2 , -S- and -0-, where R 2 is selected from the group consisting of H, Ci -6 alkyl, C,. 6 alkylenearyl, C(O)C 1-6 alkyl, C(O)aryl, SO 2 C, -6 alkyl and S0 2 aryl.
- each of L 1 and L 2 is independently selected from the group consisting of a single bond, -C(O)-, -C(O)NR 2 -, -NR 2 C(O)-, -NR 2 -, -C(O)-O-, - OC(O)- and -0-.
- each of L and L is independently selected from the group consisting of -C(O)-, -NR 2 -, -C(O)NR 2 - and - NR 2 C(O)-.
- R 2 is selected from the group consisting of H, C 1-4 alkyl, Ci -4 alkylenearyl, C(O)C, -4 alkyl, C(O)Ph, SO 2 Ci_ 4 alkyl and SO 2 Ph.
- R 2 is selected from the group consisting of H, Me, Bn, C(O)Me, C(O)Ph, SO 2 Me and SO 2 Ph.
- R 2 is H.
- m is an integer between 1 and 50. In embodiments of the invention, m is an integer between 1 and 25. In further embodiments of the invention, m is an integer between 1 and 10. In still further embodiments of the invention, m is an integer between 1 and 6.
- the multifunctional bioactive compounds of the invention include those where n is an integer between O and 50. In embodiments of the invention, n is an integer between O and 25. In further embodiments of the invention, n is an integer between O and 10.
- the compounds of Formula I include those in which R 5 is selected from the group consisting of H and Ci -6 alkyl and represents the D or L configuration or mixtures thereof. In embodiments of the invention, R 5 is selected from H and Ci- 4 alkyl, specifically H and Me. In further embodiments of the invention, both * are substantially in the D configuration or both are substantially in the L configuration.
- the multifunctional bioactive compounds of the invention also include those where D is selected from the group consisting of H, Ci -6 alkyl, any side chain of an amino acid and any functionally bioactive molecule.
- D is selected from the group consisting of H, any side chain of an amino acid and any functionally active molecule.
- functionally bioactive molecule it is meant any molecule having a pharmacological effect in the subject. This pharmacological effect may be one which complements, enhances or synergizes with the immunoregulatory group A, or it may provide another therapeutic action so that when the bioactive compounds of the invention are administered to the subject, combination therapy is effected. More than one functionally bioactive molecule may be used.
- functionally active molecules include, but are not limited to, adjuvants such as palmitoyl; analgesics such as peptide analgesics; opiates and antidotes such as dermorphin, morphine, naloxone and derivatives thereof; synthetic vaccines such as antigenic determinants - T- and B-epitopes; antibiotics, such as fusidic acid, pharmaceutical pharmacophores including small molecules such as methotrexate, diclophenac, ibuprophen, indometacine, naproxen, ketoprofen; sugars; lipids; and nucleotides.
- adjuvants such as palmitoyl
- analgesics such as peptide analgesics
- opiates and antidotes such as dermorphin, morphine, naloxone and derivatives thereof
- synthetic vaccines such as antigenic determinants - T- and B-epitopes
- antibiotics such as fusi
- the multifunctional bioactive compounds of Formula I have the following formula:
- L 1 , L 2 , D, R 3 , R 4 , R 5 , m, n and * have the meanings provided above.
- the multifunctional bioactive compounds of Formula I have the following formula: D
- L 2 , D, R 3 , R 4 , R 5 , m, n and * have the meanings provided above.
- All of the compounds of the invention have more than one asymmetric centre. Where the compounds according to the invention possess more than one asymmetric centre, they may exist as diastereomers. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present invention. It is to be understood that while the relative stereochemistry of the compounds of the invention may be as shown in any given compound shown herein, such compounds of the invention may also contain certain amounts (e.g. less than 20%, preferably less than 10%, more preferably less than 5%) of compounds of the invention having alternate stereochemistry.
- the compounds of the invention can be prepared from known starting materials using procedures known in the art. Generally, the compounds are prepared by the coupling of two or more entities together, for example, using standard coupling chemistry (e.g. formation of peptide bonds, amide linkages, disulfide linkages, ester linkages, etc.).
- the diketopiperazine moiety may be prepared using known chemistry. For example, diketopiperazines can be formed by cyclodimerization of amino acid ester derivatives as described by Katchalski et al. in J. Amer. Chem.
- the chemistries used to prepare the compounds of the invention may have to be modified, for instance, by use of protective groups, to prevent side reactions due to reactive groups, such as reactive groups attached as substituents.
- protective groups to prevent side reactions due to reactive groups, such as reactive groups attached as substituents. This may be achieved by means of conventional protecting groups, for example as described in "Protective Groups in Organic Chemistry” McOmie, J.F.W. Ed., Plenum Press, 1973 and in Greene, T.W. and Wuts, P. G. M., "Protective Groups in Organic Synthesis", John Wiley & Sons, 3 rd Edition, 1999.
- a desired compound salt is achieved using standard techniques.
- the neutral compound is treated with an acid or base in a suitable solvent and the formed salt is isolated by filtration, extraction or any other suitable method.
- solvates of the compounds of the invention will vary depending on the compound and the solvate.
- solvates are formed by dissolving the compound in the appropriate solvent and isolating the solvate by cooling or using an antisolvent.
- the solvate is typically dried or azeotroped under ambient conditions.
- prodrugs of the compounds of the invention include within its scope, prodrugs of the compounds of the invention.
- prodrugs will be functional derivatives of a compound of the invention which are readily convertible in vivo into the compound from which it is notionally derived.
- Prodrugs of the compounds of the invention may be conventional esters formed with available hydroxy, thiol, amino or carboxyl group.
- an available OH or NH 2 group in a compound of the invention may be acylated using an activated acid in the presence of a base, and optionally, in inert solvent (e.g. an acid chloride in pyridine).
- prodrugs which have been utilized as prodrugs are phenyl esters, aliphatic (C 8 -C 24 ) esters, acyloxymethyl esters, carbamates and amino acid esters.
- the prodrugs of the compounds of the invention are those in which one or more of the hydroxy groups in the compounds is masked as groups which can be converted to hydroxy groups in vivo. Conventional procedures for the selection and preparation of suitable prodrugs are described, for example, in "Design of Prodrugs" ed. H. Bundgaard, Elsevier, 1985.
- the present invention includes radiolabeled forms of compounds of the invention, for example, compounds of the invention labeled by incorporation within the structure 3 H or 14 C or a radioactive halogen such as 125 I.
- a radiolabeled compound of the invention may be prepared using standard methods known in the art.
- tritium may be incorporated into a compound of the invention using standard techniques, for example, by hydrogenation of a suitable precursor to a compound of the invention using tritium gas and a catalyst.
- a compound of the invention containing radioactive iodo may be prepared from the corresponding trialkyltin (suitably trimethyltin) derivative using standard iodination conditions, such as [ 125 I] sodium iodide in the presence of chloramine-T in a suitable solvent, such as dimethylformamide.
- standard iodination conditions such as [ 125 I] sodium iodide in the presence of chloramine-T in a suitable solvent, such as dimethylformamide.
- the trialkyltin compound may be prepared from the corresponding non-radioactive halo, suitably iodo, compound using standard palladium-catalyzed stannylation conditions, for example hexamethylditin in the presence of tetrakis(triphenylphosphine) palladium (0) in an inert solvent, such as dioxane, and at elevated temperatures, suitably about 50 to 100 0 C.
- tetrakis(triphenylphosphine) palladium (0) in an inert solvent, such as dioxane
- an inert solvent such as dioxane
- the present invention includes all uses of the compounds of the invention including their use in therapeutic methods and pharmaceutical compositions, their use in diagnostic assays and their use as research tools.
- the present invention in particular relates to pharmaceutical compositions comprising a multifunctional bioactive compound of the invention and a pharmaceutically acceptable carrier.
- Also included in the present invention are methods of treating immune disorders, and optionally other disorders in the same subject, comprising administering an effective amount of a multifunctional bioactive compound of the invention to a subject in need thereof.
- the invention provides a method of modulating the immune system and/or hemopoiesis in an animal comprising administering an effective amount of a multifunctional bioactive compound of the invention to a subject in need thereof.
- a method of stimulating the immune system comprising administering an effective amount of a multifunctional bioactive compound of the invention to a subject in need thereof.
- the invention provides a method of restoring hemopoiesis in an animal with impaired hemopoiesis, for example caused by irradiation or cytostatic agents, comprising administering an effective amount of a multifunctional bioactive compound of the invention to a subject in need thereof.
- the invention provides a method of treating hemopoietic disorders, for example, without limiting to, immune cytopenia, multiple myeloma, chronic lymphoid leucosis, lymphocytic lymphomas, lymphosarcomas and in particular, B-cellular lymphoid leucosis, comprising administering an effective amount of a multifunctional bioctive compound of the invention to a subject in need thereof.
- the invention provides a method for treating immune and/or hemopoietic disorders such as cancer in an animal comprising administering an effective amount of a multifunctional bioactive compound of the invention to a subject in need thereof, possibly in combination with a cytostatic agent.
- the cytostatic agent may be, for example, oxyurea or hyperthermia.
- the invention also relates to a method of immunosuppressing an immune system in an animal comprising administering an effective amount of a multifunctional bioactive compound of the invention to a subject in need thereof.
- the compound may be administered prior to an organ or bone marrow transplant.
- the immunoregulatory properties of the compounds of the invention may be controlled, for example, by the stereochemistry in the "A" portion and "*" of the compound.
- the compounds of the invention may be used in the form of the free base, free acid, in the form of salts, solvates and/or prodrugs. All forms are within the scope of the invention.
- the described compounds, salts, prodrugs or solvates thereof may be administered to a patient in a variety of forms depending on the selected route of administration, as will be understood by those skilled in the art.
- the compositions of the invention may be administered, for example, by oral, parenteral, buccal, sublingual, nasal, rectal, patch, pump or transdermal (topical) administration and the pharmaceutical compositions formulated accordingly.
- Parenteral administration includes intravenous, intraperitoneal, subcutaneous, intramuscular, transepithelial, nasal, intrapulmonary, intrathecal, rectal and topical modes of administration. Parenteral administration may be administered by continuous infusion over a selected period of time.
- a compound of the invention may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsules, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet.
- the compound of the invention may be incorporated with excipient and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
- a compound of the invention may also be administered parenterally.
- Solutions of a compound of the invention can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose.
- Dispersions can also be prepared in glycerol, liquid polyethylene glycols, DMSO and mixtures thereof with or without alcohol, and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
- a person skilled in the art would know how to prepare suitable formulations. Conventional procedures and ingredients for the selection and preparation of suitable formulations are described, for example, in Remington's Pharmaceutical Sciences (2003 - 20th edition) and in The United States Pharmacopeia: The National Formulary (USP 24 NF 19) published in 1999.
- the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersion and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the forms must be sterile and must be fluid to the extent that easy syringability exists. Ampoules are convenient unit dosages.
- compositions for nasal administration may conveniently be formulated as aerosols, drops, gels and powders.
- Aerosol formulations typically comprise a solution or fine suspension of the active substance in a physiologically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomizing device.
- the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal after use.
- the dosage form comprises an aerosol dispenser, it will contain a propellant which can be a compressed gas such as compressed air or an organic propellant such as fluorochlorohydrocarbon.
- the aerosol dosage forms can also take the form of a pump-atomizer.
- compositions suitable for buccal or sublingual administration include tablets, lozenges, and pastilles, wherein the active ingredient is formulated with a carrier such as sugar, acacia, tragacanth, or gelatin and glycerine.
- Compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base such as cocoa butter.
- compositions for topical administration may include, for example, propylene glycol, isopropyl alcohol, mineral oil and glycerin.
- Preparations suitable for topical administration include liquid or semi-liquid preparations such as liniments, lotions, applicants, oil-in-water or water-in-oil emulsions such as creams, ointments or pastes; or solutions or suspensions such as drops.
- the topical preparations may include one or more additional ingredients such as diluents, buffers, flavoring agents, binders, surface active agents, thickeners, lubricants, preservatives, e.g. methyl hydroxybenzoate (including anti-oxidants), emulsifying agents and the like.
- Sustained or direct release compositions can be formulated, e.g. liposomes or those wherein the active compound is protected with differentially degradable coatings, such as by microencapsulation, multiple coatings, etc. It is also possible to freeze-dry the compounds of the invention and use the lypolizates obtained, for example, for the preparation of products for injection.
- the compounds of the invention may be administered to an subject alone or in combination with pharmaceutically acceptable carriers, as noted above, the proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration and standard pharmaceutical practice.
- the dosage of the compounds and/or compositions of the invention can vary depending on many factors such as the pharmacodynamic properties of the compound, the mode of administration, the age, health and weight of the recipient, the nature and extent of the symptoms, the frequency of the treatment and the type of concurrent treatment, if any, and the clearance rate of the compound in the subject to be treated.
- One of skilled in the art can determine the appropriate dosage based on the above factors.
- ointments, creams or lotions containing from 1 - 1000 ⁇ g/g of a compound of the invention may be administered.
- Oral preparations may be formulated, preferably as tablets, capsules, or drops, containing from 0.5-1000 ⁇ g of a compound of the invention per dosage unit.
- the compounds of the invention may be administered initially in a suitable dosage that may be adjusted as required, depending on the clinical response.
- a suitable dosage for ex vivo treatment of cells over a short period, for example for 30 minutes to 1 hour or longer, higher doses of compound may be used than for long term in vivo therapy.
- the compounds of the invention are also useful in diagnostic assays, screening assays and as research tools.
- the compounds of the invention may be useful in identifying or detecting an immune disorder.
- the compounds of the invention may be radiolabeled (as hereinbefore described) and contacted with a population of cells. The presence of the radiolabel on the cells may indicate an immune disorder.
- the compounds of the invention may be used to identify other compounds that modulate immune responses.
- the compounds may also be radiolabeled.
- Boc-L-Ala-ONSu (56.5 g, 0.1 mol) and 26.1 g (0.11 mol) of H-L-GIu(OBzI)-OH were mixed with 500 ml of dioxin/water (1 :1) and N-methylmorpholine (11.7 ml) until the mixture reached a pH of about 9 to 9.2. The suspension was dissolved after
- Cyclo-L-Ala-L-Glu-(OH) (2.2 g, 0.01 mol) was dissolved in 50 ml DMF and then heated to 6O 0 C. After the peptide was dissolved, the mixture was cooled to -15 0 C. Cooled to -15 0 C iso-butylchlorophormate (1.5 ml, 0.012 mol) was added, followed by the addition of 1.4 ml (0.012 mol) of N-methylmorpholine.
- H-L-Lys(Boc)-L-Glu(OBzl)-OH (23.0, 0.05 mol) was dissolved in 100 ml of pyridine and refluxed for ⁇ 4 hours.
- the reaction was monitored by TLC. After 4 hours of stirring, the solvent was evaporated in vacuum and the residual oil was dissolved in 100 ml mixture of n-butanol/water and transferred to a separation funnel. The organic layer was separated and washed with 3x50 ml of 5% H 2 SO 4 and 3x50 ml of 5% NaHCO 3 in water. N-butanol was evaporated in vacuum and ether was added to the residual oil. The precipitate was filtered off and washed with ether, and hexane. The yield was 5.0 g (88%).
- the effect of tested substances on intact bone marrow was studied in vivo.
- the peptides were introduced into mice in different manners: injected subcutaneously, intraperitoneally (IP) or introduced per os to intact donor mice, in the doses of 10- 1000 ⁇ g/kg. Two days after administration of preparation, the mice were killed. Bone marrow suspension was prepared and injected intravenously to lethally irradiated mice. The colony forming activity was evaluated at day 8. Test animals were (CBA x
- Example 5 Effects of immuno stimulant agents in vivo
- a study to compare the activity of Neogen and the new cyclic peptides of the present invention in reducing the harmful effects of ionizing radiation was performed.
- the method of exogenous spleen colonies was applied.
- a suspension of intact bone marrow cells was irradiated ex vivo in the dose of 1 Gy.
- Different doses of Neogen or cyclic peptides were injected IP, IM, subcutaneous or introduced per os to lethally irradiated recipients within an hour after the injection of irradiated bone marrow. Colonies were counted on day 8. All data in each group was the mean of three tests.
- Neogen can stimulate the regeneration process after the detrimental effect of radiation on hemopoietic precursor cells. This process was shown to be effective with IM or IP injection, but not via per os administration. New cyclic peptides under investigation possessed the same range of activity during systemic administration and are orally active at the dose range of 10 - 100 ⁇ g/kg.
- Adjuvant activity was tested on 5 groups of mice (C57B16). Each group consisted of 5 animals. Three immunizations were performed: First immunization:
- Example 8 Adjuvant activities of cyclo-L-Ala-L-Glu-(L-Trp-OH) (Compound 17), cyclo [L-Lys(Palmitoyil)-L-Glu(D-Trp-OH)] (Compound 26a), cyclo [D- Lys(Palmitoyil)-D-Glu(D-Trp-OH)] (Compound 26b), cyclo-L-Lys(N-acetyl- Glycosamine-N-acetyl-muramil)-L-Glu-(L-Trp-OH) (Compound 33a), and cyclo-D- Ly s(N-acety 1-Glycosamine-N-acety l-muramil)-D-Glu-(L-Trp-OH) (Compound 33b).
- Stage 1 Stage 1 :
- Group 1 ovalbumin 25 micrograms per animal (Mouse Nos. 1 to 7)
- Group 5 ovalbumin 25 micrograms per animal + adjuvant of compound 33a 1 microgram per animal (Mouse Nos. 28 to 35)
- Group 6 ovalbumin 25 micrograms per animal + adjuvant of compound 33b 100 micrograms per animal (No. 36 to 42)
- Group 7 ovalbumin 25 micrograms per animal + adjuvant of compound 33b 10 micrograms per animal(Mouse Nos. 43 to 49)
- Group 8 ovalbumin 25 micrograms per animal + adjuvant of compound 33b 1 microgram per animal (Mouse Nos. 50 to 56)
- Group 9 ovalbumin 25 micrograms per animal + adjuvant of compound 17 100 micrograms per animal (Mouse Nos. 57 to 63)
- OVA (10 micrograms/ml) solution in 0.05 M sodium carbonate buffer (pH 9.5) was added to plate wells, 0.1 ml per well and incubated at 4°C for 16 hours. The OVA solution was then removed and the plate was washed 4 times with PBS containing 0.05% Tween-20. Such washing was performed after each incubation stage.
- compound 17 is active at 1, 10 and 100 ⁇ g/kg; compound 19 is active at 100 ⁇ g/kg; compound 33a is active at 100 ⁇ g/kg; compound 33b is not an active compound, compound 26a is active at 10 ⁇ g/kg; and compound 26b is not an active compound.
- Peripheral opioid activity of the peptides was assessed on the basis of the ability to inhibit the electrically-induced contractions of isolated guinea pig ileum (GPI) (Kosterlitz, H. W. et al., "The effect of adrenaline, noradrenaline and isoprenaline on inhibition a- and b-adrenoreceptors in the longitudinal muscle of the guinea pig ileum", Brit. J. Pharmacol, Vol. 39., Pages 398 to 413, 1970).
- GPI isolated guinea pig ileum
- the segment of GPI about 1 cm long was placed into a 10-ml organ bath containing Krebs solution at 34 0 C.
- the composition of the Krebs solution was (mM): NaCl - 118; KCl - 4.70; CaCl 2 - 2.52; KH 2 PO 4 - 0.93; MgSO 4 - 1.27; NaHCO 3 - 25; glucose - 1 1.0. Resting tension of the organ was 1 g.
- the segment of GPI was stimulated by single pulses duration 1 ms with 0.1 Hz at 80 V.
- the solution with isolated organs was constantly aerated. The contractions were recorded in an isometrical mode by a sensor K 30 (Hugo Sachs Elektronic KG) with paper register Rikadenki-series (Japan).
- the substances tested were dissolved in distilled water and added cumulatively to the organ bath at a volume of 5 to 30 mcl. Each subsequent substance was added after the isolated organs were washed 3 or 4 times for 12-15 min. On the basis of the data obtained, dose-effects curves were plotted and the activity of substances was expressed by IC 50 or pD 2 .
- the pD 2 index was equal to a negative decimal logarithm of the substance concentration causing a 50% of the maximal effect.
- New dermorphin analogues were tested in the standard model of Guinea pig ileum binding test. For each molecule, the EC 5O was determined as concentration of substance causing the reduction of contraction amplitude by the 50% from basic level.
- mice Fl(CBAxC57D16) first generation hybrids were used for testing of analgesic activity using the "tail flick" test.
- the water temperature was at 48° C.
- the maximal effect was for the period of 30 seconds.
- All peptides were injected intraperitoneally in the doses of 5, 10 or 20 mg/kg.
- Analgesic effect was estimated in the time interval of 15 to 120 min after peptide injection.
- Student's t-criterion was used for statistical calculations of the results. Statistical significance were at the level of p ⁇ 0.05. The results of the tests are shown in Table 10.
- Antinociceptive activity of the peptides of the present invention was assessed in experiments on BALB/c male mice weighing 22 to 24 g.
- the peptides were dissolved in saline and administered intraperitoneally or intragastrally.
- the "Tail flick" test (D'Amour, F.E. et al. "A Method for Determining Loss of Pain Sensation", J. Pharmacol. Exp. Ther., Vol. 72, Pages 74 to 79, 1941) was performed on an analgesimeter type 812, Hugo Sachs Electronick KG.
- Antinociceptive activity was defined as the absence of tail flick response on stimulation with a focused bundle of heat radiation with 6 sec at baseline response of 2.0 - 3.0 seconds.
- Table 1 Examples of multifunctional bioactive compounds and pharmaceutically acceptable salts, solvates and prodrugs thereof of the present invention.
- Table 1 Examples of multifunctional bioactive compounds and pharmaceutically acceptable salts, solvates and prodrugs thereof of the present invention (Continued).
- Table 2 Spleen colony formation by bone marrow cells of novel peptides- treated mice.
- Table 3 Comparison of the activities of novel compounds of the invention and thymodepressin on the suppression of CFU-S population in the bone marrow.
- Table 4 Effect of Neogen or novel cyclic peptides of the invention on the formation of exogenous spleen colonies by irradiating bone marrow in vitro with 1 Gy.
- Table 7 Anti-OVA antibody titers following protein-adjuvant immunizations and corresponding stimulation indices.
- Table 8 Stimulation Indices for adjuvants compounds 26a and 26b.
- Table 9 In vitro (GPI - ⁇ -receptor binding activity) test results of the peripheral opioid activity of peptides.
- Table 10 Analgesic activity of opioid peptide analogues.
- Table 11 Analgesic activity of Dermorphin and analogues after oral administration as determined from the "tail flick” test. Statistically significant data (p ⁇ 0.05) shown in bold.
- Table 12 Analgesic activity of Dermorphin and analogues after intraperitoneal administration.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2009001351A MX2009001351A (en) | 2006-08-04 | 2007-08-01 | Multifunctional bioactive compounds. |
CA 2659875 CA2659875C (en) | 2006-08-04 | 2007-08-01 | Multifunctional bioactive compounds |
EP07785022.0A EP2046778B1 (en) | 2006-08-04 | 2007-08-01 | Multifunctional bioactive compounds |
EA200970178A EA018548B1 (en) | 2006-08-04 | 2007-08-01 | Multifunctional bioactive compounds |
JP2009522067A JP5357022B2 (en) | 2006-08-04 | 2007-08-01 | Multifunctional bioactive compounds |
AU2007280995A AU2007280995C1 (en) | 2006-08-04 | 2007-08-01 | Multifunctional bioactive compounds |
US12/376,138 US8637521B2 (en) | 2006-08-04 | 2007-08-01 | Substituted piperazin-2,5-diones and their use as multifunctional bioactive compounds |
BRPI0714616-7A2A BRPI0714616A2 (en) | 2006-08-04 | 2007-08-01 | multifunctional bioactive compound, pharmaceutical composition, and use of a |
CN200780033302.7A CN101511823B (en) | 2006-08-04 | 2007-08-01 | Multifunctional bioactive compounds |
HK09103863A HK1124608A1 (en) | 2006-08-04 | 2009-04-27 | Multifunctional bioactive compounds |
US14/134,418 US9108931B2 (en) | 2006-08-04 | 2013-12-19 | Substituted piperazin-2,5-diones as multifunctional bioactive compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83542806P | 2006-08-04 | 2006-08-04 | |
US60/835,428 | 2006-08-04 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/376,138 A-371-Of-International US8637521B2 (en) | 2006-08-04 | 2007-08-01 | Substituted piperazin-2,5-diones and their use as multifunctional bioactive compounds |
US14/134,418 Division US9108931B2 (en) | 2006-08-04 | 2013-12-19 | Substituted piperazin-2,5-diones as multifunctional bioactive compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008014613A1 true WO2008014613A1 (en) | 2008-02-07 |
Family
ID=38996830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2007/001357 WO2008014613A1 (en) | 2006-08-04 | 2007-08-01 | Multifunctional bioactive compounds |
Country Status (11)
Country | Link |
---|---|
US (2) | US8637521B2 (en) |
EP (1) | EP2046778B1 (en) |
JP (1) | JP5357022B2 (en) |
CN (1) | CN101511823B (en) |
AU (1) | AU2007280995C1 (en) |
BR (1) | BRPI0714616A2 (en) |
CA (1) | CA2659875C (en) |
EA (1) | EA018548B1 (en) |
HK (1) | HK1124608A1 (en) |
MX (1) | MX2009001351A (en) |
WO (1) | WO2008014613A1 (en) |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2121729A1 (en) * | 2006-12-19 | 2009-11-25 | Apotex Technologies Inc. | Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture |
WO2011017799A1 (en) | 2009-08-10 | 2011-02-17 | Immunotech Developments Inc. | Vaccine having a peptide adjuvant for eliciting a specific immune response to treat viral infection and other conditions |
JP2012514008A (en) * | 2008-12-29 | 2012-06-21 | マンカインド コーポレイション | Substituted diketopiperazine analogues for drug delivery agents |
WO2013166110A1 (en) * | 2012-05-02 | 2013-11-07 | Yale University | Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms) |
US8653080B2 (en) | 2009-01-14 | 2014-02-18 | Salk Institute For Biological Studies | Methods for screening and compounds that protect against amyloid diseases |
US9192675B2 (en) | 2008-06-13 | 2015-11-24 | Mankind Corporation | Dry powder inhaler and system for drug delivery |
US9220687B2 (en) | 2008-12-29 | 2015-12-29 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US9233159B2 (en) | 2011-10-24 | 2016-01-12 | Mannkind Corporation | Methods and compositions for treating pain |
US9241903B2 (en) | 2006-02-22 | 2016-01-26 | Mannkind Corporation | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
US9283193B2 (en) | 2005-09-14 | 2016-03-15 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
US9364619B2 (en) | 2008-06-20 | 2016-06-14 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
US9364436B2 (en) | 2011-06-17 | 2016-06-14 | Mannkind Corporation | High capacity diketopiperazine microparticles and methods |
EP2877486A4 (en) * | 2012-07-24 | 2016-08-24 | Manus Pharmaceuticals Canada Ltd | Peptide-based compounds and uses thereof to treat beta-amyloid accumulation |
US9630930B2 (en) | 2009-06-12 | 2017-04-25 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
US9662461B2 (en) | 2008-06-13 | 2017-05-30 | Mannkind Corporation | Dry powder drug delivery system and methods |
US9675674B2 (en) | 2004-08-23 | 2017-06-13 | Mannkind Corporation | Diketopiperazine salts for drug delivery and related methods |
US9700690B2 (en) | 2002-03-20 | 2017-07-11 | Mannkind Corporation | Inhalation apparatus |
US9706944B2 (en) | 2009-11-03 | 2017-07-18 | Mannkind Corporation | Apparatus and method for simulating inhalation efforts |
US9796688B2 (en) | 2004-08-20 | 2017-10-24 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
US9802012B2 (en) | 2012-07-12 | 2017-10-31 | Mannkind Corporation | Dry powder drug delivery system and methods |
US9801925B2 (en) | 1999-06-29 | 2017-10-31 | Mannkind Corporation | Potentiation of glucose elimination |
US9925144B2 (en) | 2013-07-18 | 2018-03-27 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
US9943571B2 (en) | 2008-08-11 | 2018-04-17 | Mannkind Corporation | Use of ultrarapid acting insulin |
US9983108B2 (en) | 2009-03-11 | 2018-05-29 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10342938B2 (en) | 2008-06-13 | 2019-07-09 | Mannkind Corporation | Dry powder drug delivery system |
US10421729B2 (en) | 2013-03-15 | 2019-09-24 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
US10625034B2 (en) | 2011-04-01 | 2020-04-21 | Mannkind Corporation | Blister package for pharmaceutical cartridges |
US11446127B2 (en) | 2013-08-05 | 2022-09-20 | Mannkind Corporation | Insufflation apparatus and methods |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013119955A1 (en) | 2012-02-09 | 2013-08-15 | Novus International Inc. | Functionalized polymer compositions |
CN107753462B (en) | 2012-07-12 | 2021-01-08 | 诺华丝国际股份有限公司 | Matrix and layer compositions for protecting bioactive agents |
US10584306B2 (en) | 2017-08-11 | 2020-03-10 | Board Of Regents Of The University Of Oklahoma | Surfactant microemulsions |
CN110054619A (en) * | 2018-01-18 | 2019-07-26 | 西北农林科技大学 | Novel diketopiperazine histone deacetylases inhibitor |
CN113163918B (en) * | 2018-08-28 | 2023-03-28 | 灵动科技(北京)有限公司 | Autopilot system with inventory carrying trolley |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1257265A (en) * | 1984-11-02 | 1989-07-11 | Norihiko Shimazaki | Piperazine compound, preparation thereof and use thereof |
US5932579A (en) * | 1996-06-18 | 1999-08-03 | Affymax Technologies N.V. | Collagenase-1 and stromelysin-1 inhibitors, pharmaceutical compositions comprising same and methods of their use |
CA2417960A1 (en) * | 2000-08-04 | 2002-02-14 | Dmi Biosciences, Inc. | Method of using diketopiperazines and composition containing them |
US20030028250A1 (en) | 1999-10-22 | 2003-02-06 | Archus Orthopedics, Inc. | Prostheses, systems and methods for replacement of natural facet joints with artifical facet joint surfaces |
US20030155993A1 (en) | 2002-02-15 | 2003-08-21 | Yuichi Takamine | Surface acoustic wave device and communication apparatus |
US20030198658A1 (en) | 1994-09-30 | 2003-10-23 | Emisphere Technologies, Inc. | Carbon-substituted diketopiperazine delivery systems |
CA2523467A1 (en) * | 2003-05-15 | 2004-12-02 | Dmi Biosciences, Inc. | Treatment of t-cell mediated diseases |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4006261A (en) * | 1973-09-28 | 1977-02-01 | Firmenich S.A. | Flavoring with mixtures of theobromine and cyclic dipeptides |
US4331595A (en) * | 1980-06-23 | 1982-05-25 | Ortho Pharmaceutical Corporation | Immunoregulatory diketopiperazine compounds |
US4289759A (en) * | 1980-06-23 | 1981-09-15 | Ortho Pharmaceutical Corporation | Immunoregulatory diketopiperazine compounds |
DE3909379A1 (en) | 1989-03-22 | 1990-09-27 | Cassella Ag | THIENYLPIPERAZINE, METHOD FOR THE PRODUCTION THEREOF, THE USE THEREOF AND THE MEDICAMENTS CONTAINING THEIR AND THEIR MANUFACTURE |
US5693338A (en) * | 1994-09-29 | 1997-12-02 | Emisphere Technologies, Inc. | Diketopiperazine-based delivery systems |
FR2677361A1 (en) | 1991-06-04 | 1992-12-11 | Adir | NOVEL PEPTIDES AND PSEUDOPEPTIDES, TACHYKININ DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
AU2905092A (en) | 1991-10-28 | 1993-06-07 | Cytoven | Pharmaceutical dipeptide compositions and methods of use thereof |
US5352461A (en) * | 1992-03-11 | 1994-10-04 | Pharmaceutical Discovery Corporation | Self assembling diketopiperazine drug delivery system |
FR2722787B1 (en) * | 1994-07-21 | 1996-10-11 | Univ Claude Bernard Lyon | COMPOUNDS WITH ANTHELMINTHIC ACTIVITY: DICETOPIPERAZINES, PRECURSORS AND THE LIKE |
US6103699A (en) * | 1996-06-07 | 2000-08-15 | Immunotech Developments Inc. | Peptide, a method for its preparation and a pharmaceutical composition containing the peptide |
US6060452A (en) * | 1996-03-13 | 2000-05-09 | Cytran, Inc. | Analogs of L-Glu-L-Trp having pharmacological activity |
JPH10226615A (en) * | 1997-02-18 | 1998-08-25 | Pola Chem Ind Inc | Composition containing aspartic acid-phenylalanine cyclic dipeptide derivative |
US7026322B2 (en) * | 1998-11-12 | 2006-04-11 | Nereus Pharmaceuticals, Inc. | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
DE19937721A1 (en) | 1999-08-10 | 2001-02-15 | Max Planck Gesellschaft | New diketopiperazines |
JP2001247566A (en) * | 2000-03-03 | 2001-09-11 | Marine Biotechnol Inst Co Ltd | New antimycotic substance and method of producing the substance |
US20030171379A1 (en) * | 2001-12-28 | 2003-09-11 | Jacobs Robert S. | Methods of treating, preventing, or inhibiting inflammation with Mactanamide compounds |
ES2540886T3 (en) * | 2004-08-23 | 2015-07-14 | Mannkind Corporation | Dicetopiperazine salts for drug administration |
-
2007
- 2007-08-01 EP EP07785022.0A patent/EP2046778B1/en active Active
- 2007-08-01 CA CA 2659875 patent/CA2659875C/en active Active
- 2007-08-01 BR BRPI0714616-7A2A patent/BRPI0714616A2/en not_active Application Discontinuation
- 2007-08-01 MX MX2009001351A patent/MX2009001351A/en active IP Right Grant
- 2007-08-01 JP JP2009522067A patent/JP5357022B2/en not_active Expired - Fee Related
- 2007-08-01 WO PCT/CA2007/001357 patent/WO2008014613A1/en active Application Filing
- 2007-08-01 EA EA200970178A patent/EA018548B1/en not_active IP Right Cessation
- 2007-08-01 AU AU2007280995A patent/AU2007280995C1/en not_active Ceased
- 2007-08-01 US US12/376,138 patent/US8637521B2/en active Active
- 2007-08-01 CN CN200780033302.7A patent/CN101511823B/en not_active Expired - Fee Related
-
2009
- 2009-04-27 HK HK09103863A patent/HK1124608A1/en not_active IP Right Cessation
-
2013
- 2013-12-19 US US14/134,418 patent/US9108931B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1257265A (en) * | 1984-11-02 | 1989-07-11 | Norihiko Shimazaki | Piperazine compound, preparation thereof and use thereof |
US20030198658A1 (en) | 1994-09-30 | 2003-10-23 | Emisphere Technologies, Inc. | Carbon-substituted diketopiperazine delivery systems |
US5932579A (en) * | 1996-06-18 | 1999-08-03 | Affymax Technologies N.V. | Collagenase-1 and stromelysin-1 inhibitors, pharmaceutical compositions comprising same and methods of their use |
US20030028250A1 (en) | 1999-10-22 | 2003-02-06 | Archus Orthopedics, Inc. | Prostheses, systems and methods for replacement of natural facet joints with artifical facet joint surfaces |
CA2417960A1 (en) * | 2000-08-04 | 2002-02-14 | Dmi Biosciences, Inc. | Method of using diketopiperazines and composition containing them |
US20030155993A1 (en) | 2002-02-15 | 2003-08-21 | Yuichi Takamine | Surface acoustic wave device and communication apparatus |
CA2523467A1 (en) * | 2003-05-15 | 2004-12-02 | Dmi Biosciences, Inc. | Treatment of t-cell mediated diseases |
Non-Patent Citations (6)
Title |
---|
GREENE, T.W.; WUTS, P.G.M.: "Protective Groups in Organic Synthesis, 3rd Edition,", 1999, JOHN WILEY & SONS |
H. BUNDGAARD;: "Design of Prodrugs", 1985, ELSEVIER |
KATCHALSKI ET AL., J. AMER. CHEM. SOC., vol. 68, 1946, pages 879 - 880 |
KOPPLE ET AL., J. ORG. CHEM., vol. 33, no. 2, 1968, pages 862 - 864 |
MCOMIE, J.F.W.: "Protective Groups in Organic Chemistry", 1973, PLENUM PRESS |
See also references of EP2046778A4 * |
Cited By (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9801925B2 (en) | 1999-06-29 | 2017-10-31 | Mannkind Corporation | Potentiation of glucose elimination |
US9700690B2 (en) | 2002-03-20 | 2017-07-11 | Mannkind Corporation | Inhalation apparatus |
US9796688B2 (en) | 2004-08-20 | 2017-10-24 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
US10130685B2 (en) | 2004-08-23 | 2018-11-20 | Mannkind Corporation | Diketopiperazine salts for drug delivery and related methods |
US9675674B2 (en) | 2004-08-23 | 2017-06-13 | Mannkind Corporation | Diketopiperazine salts for drug delivery and related methods |
US9283193B2 (en) | 2005-09-14 | 2016-03-15 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
US10143655B2 (en) | 2005-09-14 | 2018-12-04 | Mannkind Corporation | Method of drug formulation |
US9717689B2 (en) | 2005-09-14 | 2017-08-01 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
US9446001B2 (en) | 2005-09-14 | 2016-09-20 | Mannkind Corporation | Increasing drug affinity for crystalline microparticle surfaces |
US9241903B2 (en) | 2006-02-22 | 2016-01-26 | Mannkind Corporation | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
US10130581B2 (en) | 2006-02-22 | 2018-11-20 | Mannkind Corporation | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
EP2121729A4 (en) * | 2006-12-19 | 2013-07-31 | Apotex Technologies Inc | Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture |
EP2121729A1 (en) * | 2006-12-19 | 2009-11-25 | Apotex Technologies Inc. | Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture |
US10751488B2 (en) | 2008-06-13 | 2020-08-25 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US10342938B2 (en) | 2008-06-13 | 2019-07-09 | Mannkind Corporation | Dry powder drug delivery system |
US9446133B2 (en) | 2008-06-13 | 2016-09-20 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US9192675B2 (en) | 2008-06-13 | 2015-11-24 | Mankind Corporation | Dry powder inhaler and system for drug delivery |
US9511198B2 (en) | 2008-06-13 | 2016-12-06 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US10201672B2 (en) | 2008-06-13 | 2019-02-12 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US9339615B2 (en) | 2008-06-13 | 2016-05-17 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US9662461B2 (en) | 2008-06-13 | 2017-05-30 | Mannkind Corporation | Dry powder drug delivery system and methods |
US9364619B2 (en) | 2008-06-20 | 2016-06-14 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
US10675421B2 (en) | 2008-06-20 | 2020-06-09 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
US9943571B2 (en) | 2008-08-11 | 2018-04-17 | Mannkind Corporation | Use of ultrarapid acting insulin |
JP2012514008A (en) * | 2008-12-29 | 2012-06-21 | マンカインド コーポレイション | Substituted diketopiperazine analogues for drug delivery agents |
US10172850B2 (en) | 2008-12-29 | 2019-01-08 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US9220687B2 (en) | 2008-12-29 | 2015-12-29 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US9655850B2 (en) | 2008-12-29 | 2017-05-23 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US8653080B2 (en) | 2009-01-14 | 2014-02-18 | Salk Institute For Biological Studies | Methods for screening and compounds that protect against amyloid diseases |
US9983108B2 (en) | 2009-03-11 | 2018-05-29 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
US9630930B2 (en) | 2009-06-12 | 2017-04-25 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
WO2011017799A1 (en) | 2009-08-10 | 2011-02-17 | Immunotech Developments Inc. | Vaccine having a peptide adjuvant for eliciting a specific immune response to treat viral infection and other conditions |
EP2464379A4 (en) * | 2009-08-10 | 2013-02-20 | Immunotech Dev Inc | Vaccine having a peptide adjuvant for eliciting a specific immune response to treat viral infection and other conditions |
EP2464379A1 (en) * | 2009-08-10 | 2012-06-20 | Immunotech Developments Inc. | Vaccine having a peptide adjuvant for eliciting a specific immune response to treat viral infection and other conditions |
US9706944B2 (en) | 2009-11-03 | 2017-07-18 | Mannkind Corporation | Apparatus and method for simulating inhalation efforts |
US10625034B2 (en) | 2011-04-01 | 2020-04-21 | Mannkind Corporation | Blister package for pharmaceutical cartridges |
US9364436B2 (en) | 2011-06-17 | 2016-06-14 | Mannkind Corporation | High capacity diketopiperazine microparticles and methods |
US10130709B2 (en) | 2011-06-17 | 2018-11-20 | Mannkind Corporation | High capacity diketopiperazine microparticles and methods |
US9610351B2 (en) | 2011-10-24 | 2017-04-04 | Mannkind Corporation | Methods and compositions for treating pain |
US10258664B2 (en) | 2011-10-24 | 2019-04-16 | Mannkind Corporation | Methods and compositions for treating pain |
US9233159B2 (en) | 2011-10-24 | 2016-01-12 | Mannkind Corporation | Methods and compositions for treating pain |
WO2013166110A1 (en) * | 2012-05-02 | 2013-11-07 | Yale University | Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms) |
US9802012B2 (en) | 2012-07-12 | 2017-10-31 | Mannkind Corporation | Dry powder drug delivery system and methods |
US9718869B2 (en) | 2012-07-24 | 2017-08-01 | Manus Pharmaceuticals (Canada) Ltd. | Peptide-based compounds and uses thereof to treat beta-amyloid accumulation |
EP2877486A4 (en) * | 2012-07-24 | 2016-08-24 | Manus Pharmaceuticals Canada Ltd | Peptide-based compounds and uses thereof to treat beta-amyloid accumulation |
US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
US10421729B2 (en) | 2013-03-15 | 2019-09-24 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
US9925144B2 (en) | 2013-07-18 | 2018-03-27 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
US11446127B2 (en) | 2013-08-05 | 2022-09-20 | Mannkind Corporation | Insufflation apparatus and methods |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
Also Published As
Publication number | Publication date |
---|---|
CN101511823B (en) | 2014-07-30 |
EA200970178A1 (en) | 2009-08-28 |
EP2046778A4 (en) | 2010-09-08 |
BRPI0714616A2 (en) | 2013-06-11 |
EP2046778B1 (en) | 2013-12-04 |
JP2009545534A (en) | 2009-12-24 |
US9108931B2 (en) | 2015-08-18 |
HK1124608A1 (en) | 2009-07-17 |
JP5357022B2 (en) | 2013-12-04 |
US8637521B2 (en) | 2014-01-28 |
CN101511823A (en) | 2009-08-19 |
EA018548B1 (en) | 2013-08-30 |
AU2007280995B2 (en) | 2012-05-03 |
AU2007280995C1 (en) | 2013-05-23 |
AU2007280995A1 (en) | 2008-02-07 |
CA2659875C (en) | 2015-01-27 |
US20140179708A1 (en) | 2014-06-26 |
CA2659875A1 (en) | 2008-02-07 |
US20100048586A1 (en) | 2010-02-25 |
MX2009001351A (en) | 2009-05-11 |
EP2046778A1 (en) | 2009-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007280995B2 (en) | Multifunctional bioactive compounds | |
EP3521301B1 (en) | Polyamide compound and use thereof | |
EP0148133B1 (en) | Tripeptide compounds containing pyroglutamic acid and tryptophan, process for their production and therapeutic applications | |
IE58273B1 (en) | Novel peptide derivatives having a nitrogenous polycyclic structure, process for the preparation thereof and pharmaceutical compositions containing them | |
HU204284B (en) | Process for producing peptide derivatives containing oxa- or aza-cyclostatine | |
CA2126697A1 (en) | Opioid peptides | |
JPH0359920B2 (en) | ||
CA2706525C (en) | Novel immunoregulatory peptides, compositions, and uses thereof | |
Thierry et al. | Synthesis and activity of NAcSerAspLysPro analogs on cellular interactions between T-cell and erythrocytes in rosette formation | |
CA2185212A1 (en) | Peptide derivatives | |
US6228841B1 (en) | Peptide derivatives | |
EP0309971A2 (en) | New spergualin-related compound and pharmaceutical composition | |
EP0204374A2 (en) | Tripeptidic compounds having hypotensive activity | |
JP3554399B2 (en) | Peptide derivatives | |
EP0050856B1 (en) | New peptide, process for its preparation and pharmaceutical composition containing it | |
JPS6054400A (en) | Tetrapeptide | |
US20010007016A1 (en) | Peptide derivatives | |
JP2018515601A (en) | Pharmaceutical compounds | |
JPH0656886A (en) | New peptide derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780033302.7 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007785022 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07785022 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007280995 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2659875 Country of ref document: CA Ref document number: 2009522067 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2009/001351 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007280995 Country of ref document: AU Date of ref document: 20070801 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 475/MUMNP/2009 Country of ref document: IN Ref document number: 200970178 Country of ref document: EA |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12376138 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0714616 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090203 |